Literature DB >> 1826956

Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response?

B G Hansson1, K Riesbeck, E Nordenfelt, O Weiland.   

Abstract

Foscarnet has been shown to inhibit the proliferation of human T and B lymphocytes in vitro. The production of lymphokines was more strongly affected than the DNA synthesis. Monocyte function was only partly inhibited by the highest foscarnet concentration tried. The influence of foscarnet on the immune system could explain the beneficial effect observed in patients with HBV-related fulminant hepatitis treated with foscarnet.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826956

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  5 in total

Review 1.  Life cycle and pathogenesis of hepatitis D virus: A review.

Authors:  Zaigham Abbas; Rafia Afzal
Journal:  World J Hepatol       Date:  2013-12-27

Review 2.  Hepatitis D virus coinfection and superinfection.

Authors:  Francesco Negro
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

3.  The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B.

Authors:  Keiichi Fujiwara; Shin Yasui; Koichiro Okitsu; Yutaka Yonemitsu; Shigeto Oda; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2010-07-09       Impact factor: 7.527

4.  Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnet.

Authors:  R Schvarcz; B G Hansson; J O Lernestedt; O Weiland
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

Review 5.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.